secwatch.observer — SEC 8-K summary
======================================

Issuer:     GENELUX Corp (GNLX)
CIK:        0001231457
Form:       8-K
Filed at:   2026-01-02T23:59:59+00:00
Accession:  0001493152-26-000115
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genelux appoints Jason Litten as CMO after Paul Scigalla resigns
----------------------------------------------------------------

- Paul Scigalla, M.D., resigned as CMO effective December 30, 2025.
- Jason Litten, M.D., appointed CMO effective January 2, 2026; previously CMO at Chimeric Therapeutics.
- Dr. Litten receives base salary of $475,000/year, 40% target bonus, and option to purchase 275,000 shares vesting over 4 years.
- Severance: 6 months salary (non-CIC) or 12 months (CIC) plus COBRA coverage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/0001493152-26-000115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1231457/000149315226000115/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-000115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer